3 hours Ago By ABMN Staff
Mural Oncology ( NASDAQ:MURA – Get Free Report ) is one of 1,049 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Mural Oncology to similar companies based on the strength of its valuation, earnings, risk, profitability, dividends, analyst recommendations and institutional ownership. Earnings and Valuation This table compares Mural Oncology and its competitors revenue, earnings per share and valuation. Mural Oncology’s competitors have higher revenue and earnings than Mural Oncology.
Mural Oncology is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry. Profitability Institutional and Insider Ownership 80.2% of Mural Oncology shares are held by institutional investors.
Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 0.
1% of Mural Oncology shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are held by insiders.
Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Analyst Recommendations This is a breakdown of recent recommendations and price targets for Mural Oncology and its competitors, as reported by MarketBeat.com.
Mural Oncology presently has a consensus target price of $16.00, suggesting a potential upside of 307.12%.
As a group, “Pharmaceutical preparations” companies have a potential upside of 71.10%. Given Mural Oncology’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Mural Oncology is more favorable than its competitors.
Summary Mural Oncology beats its competitors on 8 of the 12 factors compared. About Mural Oncology ( Get Free Report ) Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.
It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Receive News & Ratings for Mural Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mural Oncology and related companies with MarketBeat.com's FREE daily email newsletter ..
